Abstract:Background: Treatment with sofosbuvir/velpatasvir has resulted in high sustained virologic response rates in HCV-infected patients with genotype 1 to 6 in clinical trials and real-world settings, but its efficacy and safety has not been assessed in Asia, a region with diverse HCV genotypes. Methods: Patients in China, Thailand, Vietnam, Singapore, and Malaysia with genotype 1-6 HCV infection who were HCV treatment naive or treatment experienced, without cirrhosis or with compensated cirrhosis, were treated with open-label sofosbuvir/velpatasvir for 12 weeks. The primary efficacy endpoint was sustained virologic response 12 weeks after completing treatment (SVR12). The primary safety endpoint was adverse events leading to premature discontinuation of study drug; serious adverse events were also evaluated. The presence of resistance-associated substitutions (RASs) was evaluated by viral sequencing. Findings: Of the 375 patients in the study, 362 patients (97%) achieved SVR12 (95% CI: 94.1% to 98.1%). The SVR12 rate was >99% for patients with genotype 1, 2, or 6 HCV infection and 86% for patients with genotype 3. Among patients with genotype 3b, nearly all of whom had baseline NS5A RASs, the SVR12 rate was 89% in noncirrhotics (25 of 28 patients) and 50% in cirrhotics (7 of 14 patients). Overall, 47% of patients had baseline NS5A RASs, 94% of whom achieved SVR12. The most common adverse events were upper respiratory tract infection (10%) and headache (5%). There were no discontinuations due to adverse events; serious adverse events were reported in 3 patients (0.8%), none of which were assessed by the investigator as related to sofosbuvir/velpatasvir treatment. Interpretation: Consistent with data from Phase 3 studies, treatment with the single-tablet regimen of sofosbuvir/velpatasvir for 12 weeks provided high overall SVR12 rates in Asian patients, but those with genotype 3b and cirrhosis had lower rates of SVR12. Trial Registration Number: NCT02671500 Funding: Funding for this study was provided by Gilead Sciences. Declaration of Interest: Lai WEI has received research funding from AbbVie, Bristol-Myers Squibb, and Roche. Teerha PIRATVISUTH has served on advisory boards for Bristol-Myers Squibb, Bayer, and Mylan, has served as a speaker for Bristol-Myers Squibb, MSD, Bayer, and Mylan, and has received research funding from Bristol-Myers Squibb, Gilead, MSD, Fibrogen, and Bayer. Chee-Kiat TAN has served on advisory boards and as a speaker for Gilead. Luisa M. STAMM, Sophia LU, Hadas DVORY-SOBOL, Hongmei MO, and Diana M. BRAINARD are employees of and hold stock in Gilead. The remaining authors declare no conflicts of interest. Ethical Approval: Prior to enrollment and before any study procedures were conducted, written informed consent was obtained from all patients. The study was approved by the independent ethics committees at all participating sites and was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice.

P0711 : Genome-wide Association Study of Response to Sofosbuvir-Ribavirin Treatment in GT2/3 HCV Patients

Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure

Association of Single Nucleotide Polymorphisms in Interferon Signaling Pathway Genes and Interferon-Stimulated Genes with the Response to Interferon Therapy for Chronic Hepatitis C

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection

Clinical Efficacy and Safety of Sofosbuvir Tablets Combined with Ribavirin in Treatment of Treatment-Nave Patients with Genotype 2 Chronic Hepatitis C Virus Infection

[A Phase II, Single-Arm, Open-Label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Sofosbuvir Combined with Ribavirin in Patients with Genotype 2 Chronic Hepatitis C Virus Infection].

Sofosbuvir/Velpatasvir for Treatment of Hepatitis C Virus in Asia: an Open-Label, Phase 3 Study

The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients

Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir

High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting

Sofosbuvir plus ribavirin with or without peginterferon for the treatment of HCV: Results from a Phase 3b study in China.

Treatment of Chronic Hepatitis C Viral Infection with Sofosbuvir and Daclatasvir in Kidney Transplant Recipients

P414 ASSESSMENT OF THE CHANGE IN ESTIMATED GLOMERULAR FILTRATION RATES IN TELBIVUDINE- OR LAMIVUDINE-BASED TRERAPY IN PATIENTS WITH CHRONIC HEPATITIS B

Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study

Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.

Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study

Real-life Study on the Effectiveness and Safety of Sofosbuvir/velpatasvir-Based Antiviral Agents for HCV Eradication in Chinese Patients

Comparison Of Efficacy Of Sofosbuvir Plus Ribavirin In Chinese Patients With Genotype 3a Or 3b Hcv Infection

Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational study.

Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B.

Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C